[Anti-arrhythmic effectiveness of allapinin in ventricular arrhythmia in patients with circulatory failure].
Antiarrhythmic efficacy of allapinin was assessed in 15 patients with heart failure combined with ventricular arrhythmias (48 h ECG monitoring). The drug was administered against a background of maintenance therapy with digoxin at a daily dose of 75 mg (digoxin concentration in blood plasma was 1.51 +/- 0.12 ng/ml). The drug was shown to possess marked antiarrhythmic activity causing a decrease of the total number of ventricular extra systoles by an average of 72.3%, group ventricular extrasystoles--by 84.5%. The drug can be recommended in combination with cardiac glycosides to patients with severe heart failure combined with ventricular arrhythmias.
Naumov
V G
VG
Blinov
S I
SI
Khodzhakuliev
B G
BG
Vangeli
R S
RS
D000157:Aconitine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D031841:Aconitum / Q000031:analogs & derivatives*; D000328:Adult; D005117:Cardiac Complexes, Premature / Q000150:complications / Q000188:drug therapy*; D002302:Cardiac Output / Q000187:drug effects; D002303:Cardiac Output, Low / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008875:Middle Aged
C051402:allapinin; D000157:Aconitine
Antiaritmicheskaia effektivnost' allapinina pri zheludochkovykh narusheniiakh ritma u bol'nykh s nedostatochnost'iu krovo-obrashcheniia.